journal article·2026-11Open access

Vitreous humor–mimetic liposomes enable effective gene delivery to the eye via intravitreal injection

So Young Choi, Chang Sik Cho, Seongchan Kim, Jeong Hun Kim, Hyunkyung Kim, Ki Hun Kim, Dong Hyun Jo, Hyojin Lee

Biomaterials· Volume 334

Abstract

Inherited retinal disorders such as Norrie disease lack effective therapies, largely owing to the challenges of delivering genes to retinal tissues via intravitreal injection. The efficacy of gene delivery is constrained by physical impediments, including the inner limiting membrane and the viscoelastic characteristics of the vitreous humor. In this study, we present the development of vitreous humor–mimetic liposomes (VMLs), which have been shown to facilitate efficient retinal gene delivery by enhancing biocompatibility and tissue absorption. The VMLs were engineered by reproducing the lipidomic composition of the native vitreous, as identified through liquid chromatography–mass spectrometry analysis. The subretinal injection of VMLs was conducted to assess the efficiency of gene expression delivery by VMLs. Notably, VML #3 demonstrated a 1.3-fold enhanced GFP transfection compared to conventional nanoparticle, Lipofectamine 2000. Following intravitreal administration, VML #3 facilitated efficient delivery of pGFP–NDP (Norrie disease protein) plasmids and restored retinal vascularization in both Ndp-hemizygous and oxygen-induced retinopathy mouse models. The findings demonstrate the potential of tissue-inspired nanocarriers as effective platforms for enhancing intraocular delivery, suggesting a clinically applicable strategy for the treatment of inherited retinal diseases, including Norrie disease. Intravitreal (IVT) injection is one of the most promising methods for delivering drugs into the eyes, but it is highly hindered by the high viscosity of the vitreous. Here, vitreous humor–mimetic liposomes (VML) enable efficient delivery of pGFP-NDP plasmid into the eyes. IVT injection of pGFP-NDP-loaded VML showed neovascularization in oxygen-induced retinopathy mouse models, showing therapeutic efficacy of VMLs. • Vitreous humor–mimetic liposomes (VML) enhance pGFP transfection efficiency via intravitreal injection • VML show lower toxicity and higher pGFP transfection efficiency in vivo • pGFP-NDP-encapsulating VML successfully restored vascularization in Ndp-hemizygous and oxygen induced retinopathy (OIR) mouse models.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Retinal Development and Disorders · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (28)

Show source-provided references
1. A comprehensive review of retinal gene therapy10.1038/mt.2012.280 ↗
2. Retinal gene therapy: an eye-opener of the 21st century10.1038/s41434-020-0168-2 ↗
3. Systemic gene therapy rescues retinal dysfunction and hearing loss in a model of Norrie disease10.15252/emmm.202317393 ↗
4. Current and future treatment of retinitis pigmentosa10.2147/OPTH.S370032 ↗
5. Long-term effect of gene therapy on leber's congenital amaurosis10.1056/NEJMoa1414221 ↗
6. Drug delivery systems for RNA therapeutics10.1038/s41576-021-00439-4 ↗
7. All-rounder liposomes in cancer immunotherapy: strategies and design applications of engineered liposomal nanomaterials10.1007/s13206-024-00147-1 ↗
8. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer10.1038/nature23003 ↗
9. Recent advances and future prospects: current status and challenges of the intraocular injection of drugs for vitreoretinal diseases10.1016/j.addr.2023.114870 ↗
10. RNAi-Based treatment for neovascular age-related macular degeneration by Sirna-02710.1016/j.ajo.2010.02.006 ↗
11. Intravitreal therapy for diabetic macular edema: an update10.1155/2021/6654168 ↗
12. Intravitreal medications for retinal vein occlusion: systematic review and meta-analysis10.18502/jovr.v14i3.4791 ↗
13. Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases10.1038/s41433-020-0770-y ↗
14. The vitreous humor as a barrier to nanoparticle distribution10.1089/jop.2012.0138 ↗
15. The biochemical structure of mammalian vitreous10.1038/eye.1996.159 ↗
16. Liposomes for intravitreal drug delivery: a state of the art10.1016/j.jconrel.2012.01.019 ↗
17. Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats
18. Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo10.1016/j.jconrel.2013.01.018 ↗
19. The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection10.1016/j.biomaterials.2012.01.030 ↗
20. Pharmacokinetic aspects of retinal drug delivery10.1016/j.preteyeres.2016.12.001 ↗
21. Macro- and microscale properties of the vitreous humor to inform substitute design and intravitreal biotransport10.1080/02713683.2020.1826977 ↗
22. Imidazole-based pH-Sensitive convertible liposomes for anticancer drug delivery10.3390/ph15030306 ↗
23. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models10.1038/bjc.1995.430 ↗
24. Tools for translation: non-viral materials for therapeutic mRNA delivery10.1038/natrevmats.2017.56 ↗
25. Müller glial cell reprogramming and retina regeneration10.1038/nrn3723 ↗
26. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics10.1038/s12276-023-01086-x ↗
27. Toxicity of cationic lipids and cationic polymers in gene delivery10.1016/j.jconrel.2006.04.014 ↗
28. Extracellular vesicles as a next-generation drug delivery platform10.1038/s41565-021-00931-2 ↗